Boehringer Ingelheim GmbH’s zongertinib enters the market as the first oral HER2-targeted therapy for patients with non-small ...

In less than two weeks, Setpoint Medical Inc. mastered the power serve with the first approval of a neuroimmune modulation device to manage rheumatoid arthritis, followed by a $25 million second ...

Experimental drugs that directly inhibit the NSD2 enzyme have shown potential as an effective strategy against hard-to-treat cancers, such as lung and pancreatic tumors driven by KRAS mutations. The ...

Just two days after reporting the appointment of a new CEO, Instylla Inc. said it received a premarket approval from the U.S.

Proteinqure Inc. has received regulatory clearances from the U.FDA and Health Canada to initiate a phase I trial of lead ...

Ischemic stroke triggers a strong neuroinflammatory response, with microglial activation and neutrophil infiltration ...

Although congenital aortic valve disease (AVD) is one of the most prevalent types of congenital heart disease, affecting 1% ...

Med-tech companies brought in $18.11 billion through financings in the first seven months of 2025, marking a modest rebound ...

Biopharma companies raised $34.89 billion through financings in the first seven months of 2025, including $5.66 billion in ...

The Nipah virus (NiV) from the Henipavirus genus is a bat-borne zoonotic pathogen that causes encephalitis and acute ...

In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the ...

The difference between the origin of Alzheimer's disease (AD) and its symptoms is an obstacle to finding effective treatments ...